Showing results (1421-1430 of 3,353) with videos related to
Sort By:
Pageof 336
Pharmacoeconomics|August 29, 2015
Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from CelgeneHedwig M Blommestein, Nigel Armstrong, Steve Ryder, et al.Pharmacoeconomics|August 2, 2015
The MAPS Reporting Statement for Studies Mapping onto Generic Preference-Based Outcome Measures: Explanation and ElaborationStavros Petrou, Oliver Rivero-Arias, Helen Dakin, et al.Pharmacoeconomics|August 2, 2015
Preferred Reporting Items for Studies Mapping onto Preference-Based Outcome Measures: The MAPS StatementStavros Petrou, Oliver Rivero-Arias, Helen Dakin, et al.Pharmacoeconomics|December 10, 2014
Cost effectiveness of dabrafenib as a first-line treatment in patients with BRAF V600 mutation-positive unresectable or metastatic melanoma in CanadaThomas E Delea, Jordan Amdahl, Alice Wang, et al.Pharmacoeconomics|January 11, 2015
Do Statins Reduce the Health and Health Care Costs of Obesity?Étienne Gaudette, Dana P Goldman, Andrew Messali, et al.Pharmacoeconomics|December 6, 2014
Systematic review of cost-effectiveness analyses of treatments for psoriasisWei Zhang, Nazrul Islam, Canice Ma, et al.Pharmacoeconomics|December 21, 2014
Biological therapies for the treatment of severe psoriasis in patients with previous exposure to biological therapy: a cost-effectiveness analysisLaura M Sawyer, David Wonderling, Karina Jackson, et al.Pharmacoeconomics|November 1, 2014
A primer on marginal effects-part II: health services research applicationsE Onukwugha, J Bergtold, R JainPharmacoeconomics|September 8, 2020
Correction to: Estimating Transition Probabilities from Published Evidence: A Tutorial for Decision ModelersRisha Gidwani, Louise B RussellPharmacoeconomics|November 2, 2020
Overlap of Depressive Symptoms with Health-Related Quality-of-Life MeasuresRon D Hays, Peter M FayersPageof 336